Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Cancer treatments Stories

2013-03-26 08:24:35

SAN FRANCISCO, March 26, 2013 /PRNewswire/ -- New research adds to the growing body of evidence that modified citrus pectin (MCP), a natural supplement derived from the pith of citrus fruit, has a powerful effect against cancer. In a study just published in the March 2013 issue of the journal Integrative Cancer Therapies, MCP enhanced the anti-cancer effects of two botanical formulas, one for breast cancer and one for prostate cancer. The combination treatment decreased cancer cell...

Using T Cells To Fight Childhood Leukemia
2013-03-26 05:43:28

redOrbit Staff & Wire Reports - Your Universe Online A research team from The Children's Hospital of Philadelphia and the University of Pennsylvania used a novel cell therapy to reprogram the immune cells of two leukemia patients, resulting in a complete remission of the disease and a total lack of evidence of cancer cells in their bodies. The treatment, which is described in a study that is currently available online and will appear in the April 18 print edition of the New England...

2013-03-25 12:27:13

-- CHOP/Penn Medicine Oncology Team Reports Complete Remission in Pediatric ALL Patients PHILADELPHIA, March 25, 2013 /PRNewswire-USNewswire/ -- Two children with an aggressive form of childhood leukemia had a complete remission of their disease--showing no evidence of cancer cells in their bodies--after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of...

2013-03-25 08:26:15

45 percent of Treated Lesions Demonstrated a Durable Response Of At Least 6 Months SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) - a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors - announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies...

2013-03-22 09:32:58

St. Jude Children's Research Hospital plays key role in research showing that drug shortages erode the quality and increase the cost of cancer care; experts warn that shortages persist despite efforts to fix the problem A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients, forcing treatment changes and delays that for some patients meant worse outcomes, more therapy-related complications and higher costs. St. Jude Children's...

2013-03-18 08:28:01

SAN DIEGO, March 18, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced Dr. Adil Daud, chair of OncoSec's Melanoma Advisory Board, will present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Hilton New York Hotel on Friday, March 22 at 2:25 PM ET. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Dr. Daud will...

2013-03-15 08:26:42

New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 15, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13(th) St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around...

2013-03-14 08:28:10

SAN DIEGO, March 14, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the 25(th) Annual Roth Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California, on Tuesday, March 19th at 8:00AM Pacific Time. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Mr. Dhillon will...

2013-03-13 17:50:29

Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body´s natural immune response. Oncolytic viruses have shown promise as anticancer agents, with variations of the herpes simplex virus (HSV) among the most commonly used. However, many studies have shown that the effectiveness of viral therapy to eradicate tumors has not been as successful with patients as it has been in the lab. These...

2013-03-13 08:33:48

Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive...